Hanni Menn-Josephy, MD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Nephrology

MD, Technion - Israel Institute of Technology
BSc, Ben-Gurion University of the Negev



Dr. Menn-Josephy is a board-certified nephrologist with a special interest in Autoimmune Kidney Diseases and Lupus Nephritis. She serves as the Nephrology Director of the Lupus Multidisciplinary Program at Boston Medical Center, that operates as a regional and national referral center for patients that suffer from lupus and lupus nephritis.
As part of her interest in translational research in the field of lupus nephritis, Dr. Menn-Josephy established with her colleagues an autoimmunity clinical registry and patient biobank, with the goal of studying lupus pathogenesis in order to try and identify new therapeutic targets.
Together with her colleagues, Dr. Menn-Josephy developed a unique care model that enables lupus and lupus nephritis patients to enjoy a comprehensive care from rheumatology, nephrology and dermatology disciplines, in order to improve their health and reduce health related disparities. Dr. Menn-Josephy is committed to reducing health disparities in lupus patients, and to identifying better therapeutic targets, since current treatments are non specific, have significant toxicity, and many of the patients do not achieve complete remission and struggle with compliance.
Dr. Menn-Josephy has strong commitment to education and she serves as the Associate Program Director for the Fellowship Program in the nephrology section at Boston Medical Center. Over the past years. she has been involved is establishing educational programs in the field of lupus nephritis on institutional, regional, and national levels.

Diversity, Equity, Inclusion and Accessibility

I am dedicated to reducing health disparities among our lupus and lupus nephritis patients in the lupus clinic that are from underrepresented minorities. In lupus disease, Hispanic and African American or African- Caribbean patients have increased risk for developing lupus nephritis, as well as End Stage Kidney Disease, and other lupus related complications. Our lupus program is strongly committed to address and support mental and socio-economic challenges that our patients face, and to advocate for resources to support them. In 2020, we received the Quality Improvement in Lupus Care for the Underserved award from the Department of Medicine for our work in improving compliance with appointments in our lupus clinic.

As the Associate Program Director in the Nephrology Program, I am dedicated to recruiting and creating a working and learning community that promotes and welcomes trainees from a variety of backgrounds and creates access to opportunities for a diverse collection of applicants. I am committed to mentoring and sponsoring our trainees from underrepresented minorities, and to promoting equity, diversity and inclusion in our training program.

Member
Boston University
Amyloidosis Center





A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy
01/21/2020 - 01/20/2023 (PI)
Bristol-Myers Squibb Company

Toll-like receptor Induced pathways in lupus nephritis
07/01/2016 - 12/31/2017 (PI)
National Kidney Fdtn


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Menn-Josephy H, Hodge LS, Birardi V, Leher H. Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria. Clin J Am Soc Nephrol. 2024 Mar 01; 19(3):309-318. PMID: 38110196; DOI: 10.2215/CJN.0000000000000297;
     
  2. Schmidt IM, Shohet M, Serrano M, Yadati P, Menn-Josephy H, Ilori T, Eneanya ND, Cleveland Manchanda EC, Waikar SS. Patients' Perspectives on Race and the Use of Race-Based Algorithms in Clinical Decision-Making: a Qualitative Study. J Gen Intern Med. 2023 Jul; 38(9):2045-2051.View Related Profiles. PMID: 36811702; DOI: 10.1007/s11606-023-08035-4;
     
  3. Nader R, Zhen A, Angel-Korman A, Pavlovich SS, Pogrebinsky A, Doros G, Menn-Josephy H, Stern L, Sanchorawala V, Havasi A. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. Nephrol Dial Transplant. 2022 Jun 23; 37(7):1281-1288.View Related Profiles. PMID: 34043009
     
  4. Li H, Tsokos MG, Bhargava R, Adamopoulos IE, Menn-Josephy H, Stillman IE, Rosenstiel P, Jordan J, Tsokos GC. IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. J Clin Invest. 2021 06 15; 131(12). PMID: 33956666; DOI: 10.1172/JCI142428;
     
  5. Angel-Korman A, Stern L, Angel Y, Sarosiek S, Menn-Josephy H, Francis J, Ghai S, Sloan JM, Sanchorawala V, Havasi A. The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease. Kidney Int Rep. 2020 Apr; 5(4):485-493.View Related Profiles. PMID: 32274452; DOI: 10.1016/j.ekir.2020.01.011;
     
  6. Bonegio RG, Lin JD, Beaudette-Zlatanova B, York MR, Menn-Josephy H, Yasuda K. Lupus-Associated Immune Complexes Activate Human Neutrophils in an Fc?RIIA-Dependent but TLR-Independent Response. J Immunol. 2019 02 01; 202(3):675-683.View Related Profiles. PMID: 30610165; DOI: 10.4049/jimmunol.1800300;
     
  7. Menn-Josephy H, Lee CS, Nolin A, Christov M, Rybin DV, Weinberg JM, Henderson J, Bonegio R, Havasi A. Renal Interstitial Fibrosis: An Imperfect Predictor of Kidney Disease Progression in Some Patient Cohorts. Am J Nephrol. 2016; 44(4):289-299.View Related Profiles. PMID: 27626625; DOI: 10.1159/000449511;
     
  8. Duffau P, Menn-Josephy H, Cuda CM, Dominguez S, Aprahamian TR, Watkins AA, Yasuda K, Monach P, Lafyatis R, Rice LM, Kenneth Haines G, Gravallese EM, Baum R, Richez C, Perlman H, Bonegio RG, Rifkin IR. Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. Arthritis Rheumatol. 2015 Dec; 67(12):3146-57.View Related Profiles. PMID: 26315890; PMCID: PMC4661118; DOI: 10.1002/art.39321;
     
  9. Watkins AA, Yasuda K, Wilson GE, Aprahamian T, Xie Y, Maganto-Garcia E, Shukla P, Oberlander L, Laskow B, Menn-Josephy H, Wu Y, Duffau P, Fried SK, Lichtman AH, Bonegio RG, Rifkin IR. IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. J Immunol. 2015 Feb 15; 194(4):1467-79.View Related Profiles. PMID: 25595782; PMCID: PMC4323680; DOI: 10.4049/jimmunol.1402807;
     
  10. Menn-Josephy H, Beck LH. Recurrent glomerular disease in the kidney allograft. Front Biosci (Elite Ed). 2015; 7:135-48.View Related Profiles. PMID: 25553369
     
Showing 10 of 13 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 13 publications over 10 distinct years, with a maximum of 3 publications in 2015

YearPublications
20101
20121
20141
20153
20161
20191
20201
20211
20221
20232
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Lupus
Lupus nephritis
Mechanisms of autoimmune kidney disease
Patient biobank
Mechanisms of autoimmunity
Health disparities
multidisciplinary care
Contact for Mentoring:

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Menn-Josephy's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department